Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.
Inclusion Criteria:
Exclusion Criteria:
ganataca@yahoo.com+905059284244
Patients diagnosed with Type 2 Diabetes Mellitus and diabetic polyneuropathy confirmed by clinical and electrophysiological evaluation.
Patients diagnosed with Type 2 Diabetes Mellitus without evidence of diabetic polyneuropathy.
Participants without diabetes mellitus or neuropathy.
Irisin And Diabetic Nephropathy
Irisin Expression and Gene Polymorphism in Type II Diabetic Patients With and Without CAD
Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients
The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes
Serum and Corporal Irisin Level and Its Correlation With Erectile Function in Diabetic Obese Patients
Serum Neurofilament Light Chain Levels and Neuropathy Severity in Diabetic Polyneuropathy
Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy
Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity